Exact Mass: 301.2167

Exact Mass Matches: 301.2167

Found 387 metabolites which its exact mass value is equals to given mass value 301.2167, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Dobutamine

3,4-Dihydroxy-N-[3-(4-hydroxyphenyl)-1-methylpropyl]-beta-phenylethylamine

C18H23NO3 (301.1678)


Dobutamine is only found in individuals that have used or taken this drug. It is a beta-2 agonist catecholamine that has cardiac stimulant action without evoking vasoconstriction or tachycardia. It is proposed as a cardiotonic after myocardial infarction or open heart surgery. [PubChem]Dobutamine directly stimulates beta-1 receptors of the heart to increase myocardial contractility and stroke volume, resulting in increased cardiac output. C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents KEIO_ID D185; [MS2] KO008933 KEIO_ID D185

   

Trihexyphenidyl

Pharmaceutical associates brand OF trihexyphenidyl hydrochloride

C20H31NO (301.2406)


Trihexyphenidyl is only found in individuals that have used or taken this drug. It is one of the centrally acting muscarinic antagonists used for treatment of parkinsonian disorders and drug-induced extrapyramidal movement disorders and as an antispasmodic. [PubChem]Trihexyphenidyl is a selective M1 muscarinic acetylcholine receptor antagonist. It is able to discriminate between the M1 (cortical or neuronal) and the peripheral muscarinic subtypes (cardiac and glandular). Trihexyphenidyl partially blocks cholinergic activity in the CNS, which is responsible for the symptoms of Parkinsons disease. It is also thought to increase the availability of dopamine, a brain chemical that is critical in the initiation and smooth control of voluntary muscle movement. D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

(2E,6E,8E)-N-Isobutyl-2,6,8-hexadecatriene-10-yneamide

(E,E,E)-N-(2-Methylpropyl)hexadeca-2,6,8-trien-10-ynamide

C20H31NO (301.2406)


   

(E,E)-Futoamide

(2E,6E)-7-(2H-1,3-Benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,6-dienimidate

C18H23NO3 (301.1678)


(2E,6E)-7-(1,3-benzodioxol-5-yl)-N-isobutyl-2,6-heptadienamide is a member of benzodioxoles. (E,E)-Futoamide is a natural product found in Piper longum with data available. (E,E)-Futoamide is found in herbs and spices. (E,E)-Futoamide is an alkaloid from Piper longum (long pepper Alkaloid from Piper longum (long pepper). (E,E)-Futoamide is found in herbs and spices.

   

(6E)-Piperamide-C7:1

(6Z)-7-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)hept-6-en-1-one

C18H23NO3 (301.1678)


(6E)-Piperamide-C7:1 is found in herbs and spices. (6E)-Piperamide-C7:1 is a constituent of pepper fruits (Piper nigrum). Constituent of pepper fruits (Piper nigrum). (6E)-Piperamide-C7:1 is found in herbs and spices.

   

2,6 Dimethylheptanoyl carnitine

3-[(2,6-Dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H31NO4 (301.2253)


2,6 dimethylheptanoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.) [HMDB] 2,6 dimethylheptanoyl carnitine is an acylcarnitine. Numerous disorders have been described that lead to disturbances in energy production and in intermediary metabolism in the organism which are characterized by the production and excretion of unusual acylcarnitines. A mutation in the gene coding for carnitine-acylcarnitine translocase or the OCTN2 transporter aetiologically causes a carnitine deficiency that results in poor intestinal absorption of dietary L-carnitine, its impaired reabsorption by the kidney and, consequently, in increased urinary loss of L-carnitine. Determination of the qualitative pattern of acylcarnitines can be of diagnostic and therapeutic importance. The betaine structure of carnitine requires special analytical procedures for recording. The ionic nature of L-carnitine causes a high water solubility which decreases with increasing chain length of the ester group in the acylcarnitines. Therefore, the distribution of L-carnitine and acylcarnitines in various organs is defined by their function and their physico-chemical properties as well. High performance liquid chromatography (HPLC) permits screening for free and total carnitine, as well as complete quantitative acylcarnitine determination, including the long-chain acylcarnitine profile. (PMID: 17508264, Monatshefte fuer Chemie (2005), 136(8), 1279-1291., Int J Mass Spectrom. 1999;188:39-52.).

   

Nonanoylcarnitine

3-(Nonanoyloxy)-4-(trimethylammonio)butanoic acid

C16H31NO4 (301.2253)


Nonanoylcarnitine is an acylcarnitine. More specifically, it is an nonanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy.  This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. Nonanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine nonanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. It is also decreased in the blood or plasma of individuals with psoriasis (PMID: 28695330, PMID: 33391503), pregnancy (PMID: 24704061 - in serum of pregnant women with fetus with CHD). It is also decreased in the urine of individuals with obesity (PMID: 26910390). Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews]. A human metabolite taken as a putative food compound of mammalian origin [HMDB]

   

Ractopamine

(R)-p-Hydroxy-alpha-((((R)-3-(p-hydroxyphenyl)-1-methylpropyl)amino)methyl)benzyl alcohol

C18H23NO3 (301.1678)


Ractopamine (CAS: 97825-25-7) is a beta-agonist livestock feed additive used to increase lean muscle mass. Pharmacologically, ractopamine is a TAAR1 agonist and beta adrenoreceptor agonist that stimulates beta1 and beta2 adrenergic receptors (PMID: 24799633). In clinical use, beta-agonists relax the smooth muscles of airways, thereby resulting in bronchodilation (i.e. widened airways) and easier breathing. In livestock feed, these compounds are able to alter the ratio in which dietary energy intake is distributed between lean and fat tissue. Increasing protein synthesis results in increased muscle fibre size. Ractopamine is banned in over 160 countries including the member nations of the European Union, China, and Russia. Countries such as the United States and South Korea still permit ractopamine use (PMID: 26761809). Serious side effects, including mortality, have been attributed to beta-agonists (e.g. ractopamine and zilpaterol) in cattle and swine. Cooking is not able to completely degrade ractopamine, therefore human exposure to ractopamine is expected in countries where the feed additive is permitted. In humans, beta-agonists containing phenolic hydroxyl groups, are metabolized in the liver and intestine through glucuronidation and sulfation by UDP-glucuronosyltransferase (UGT) 1A6 and 1A9 and sulfotransferase (SULT1A3). Ractopamine is eliminated in urine mostly as its monoglucuronide and monosulfate conjugates (PMID: 27641640). Butopamine, the R,R diastereoisomer, is the most active of ractopamines four diastereoisomers and is responsible for most of the leanness-enhancing effects. C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

   

3-Hydroxy-cis-5-octenoylcarnitine

3-{[(5Z)-3-hydroxyoct-5-enoyl]oxy}-4-(trimethylammonio)butanoic acid

C15H27NO5 (301.1889)


3-Hydroxy-cis-5-octenoylcarnitine is an acylcarnitine. More specifically, it is an 3-Hydroxy-cis-5-octenoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-cis-5-octenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxy-cis-5-octenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Methyloctanoylcarnitine

3-[(6-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2253)


6-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 6-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Methyloctanoylcarnitine

3-[(5-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2253)


5-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 5-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Methyloctanoylcarnitine

3-[(4-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2253)


4-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 4-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Methyloctanoylcarnitine

3-[(7-Methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C16H31NO4 (301.2253)


7-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 7-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Methyloctanoylcarnitine

3-[(3-methyloctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2253)


3-Methyloctanoylcarnitine is an acylcarnitine. More specifically, it is an 3-methyloctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Methyloctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Methyloctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxy-5-octenoylcarnitine

3-[(2-hydroxyoct-5-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


2-Hydroxy-5-octenoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyoct-5-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxy-5-octenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxy-5-octenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Hydroxy-6-octenoylcarnitine

3-[(4-hydroxyoct-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


4-Hydroxy-6-octenoylcarnitine is an acylcarnitine. More specifically, it is an 4-hydroxyoct-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-Hydroxy-6-octenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-Hydroxy-6-octenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Hydroxy-6-octenoylcarnitine

3-[(3-hydroxyoct-6-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


3-Hydroxy-6-octenoylcarnitine is an acylcarnitine. More specifically, it is an 3-hydroxyoct-6-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-Hydroxy-6-octenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-Hydroxy-6-octenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

2-Hydroxy-4-octenoylcarnitine

3-[(2-hydroxyoct-4-enoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


2-Hydroxy-4-octenoylcarnitine is an acylcarnitine. More specifically, it is an 2-hydroxyoct-4-enoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 2-Hydroxy-4-octenoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 2-Hydroxy-4-octenoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

5-Oxooctanoylcarnitine

3-[(5-oxooctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


5-oxooctanoylcarnitine is an acylcarnitine. More specifically, it is an 5-oxooctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 5-oxooctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 5-oxooctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

7-Oxooctanoylcarnitine

3-[(7-oxooctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


7-oxooctanoylcarnitine is an acylcarnitine. More specifically, it is an 7-oxooctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 7-oxooctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 7-oxooctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

6-Oxooctanoylcarnitine

3-[(6-Oxooctanoyl)oxy]-4-(trimethylazaniumyl)butanoic acid

C15H27NO5 (301.1889)


6-oxooctanoylcarnitine is an acylcarnitine. More specifically, it is an 6-oxooctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 6-oxooctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 6-oxooctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

4-Oxooctanoylcarnitine

3-[(4-oxooctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


4-oxooctanoylcarnitine is an acylcarnitine. More specifically, it is an 4-oxooctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 4-oxooctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 4-oxooctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

3-Oxooctanoylcarnitine

3-[(3-oxooctanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C15H27NO5 (301.1889)


3-oxooctanoylcarnitine is an acylcarnitine. More specifically, it is an 3-oxooctanoic acid ester of carnitine. Acylcarnitines were first discovered more than 70 year ago (PMID: 13825279). It is believed that there are more than 1000 types of acylcarnitines in the human body. The general role of acylcarnitines is to transport acyl-groups (organic acids and fatty acids) from the cytoplasm into the mitochondria so that they can be broken down to produce energy. This process is known as beta-oxidation. According to a recent review [Dambrova et al. 2021, Physiological Reviews], acylcarnitines (ACs) can be classified into 9 different categories depending on the type and size of their acyl-group: 1) short-chain ACs; 2) medium-chain ACs; 3) long-chain ACs; 4) very long-chain ACs; 5) hydroxy ACs; 6) branched chain ACs; 7) unsaturated ACs; 8) dicarboxylic ACs and 9) miscellaneous ACs. Short-chain ACs have acyl-groups with two to five carbons (C2-C5), medium-chain ACs have acyl-groups with six to thirteen carbons (C6-C13), long-chain ACs have acyl-groups with fourteen to twenty once carbons (C14-C21) and very long-chain ACs have acyl groups with more than 22 carbons. 3-oxooctanoylcarnitine is therefore classified as a medium chain AC. As a medium-chain acylcarnitine 3-oxooctanoylcarnitine is somewhat less abundant than short-chain acylcarnitines. These are formed either through esterification with L-carnitine or through the peroxisomal metabolism of longer chain acylcarnitines (PMID: 30540494). Many medium-chain acylcarnitines can serve as useful markers for inherited disorders of fatty acid metabolism. Carnitine octanoyltransferase (CrOT, EC:2.3.1.137) is responsible for the synthesis of all medium-chain (MCAC, C5-C12) and medium-length branched-chain acylcarnitines in peroxisomes (PMID: 10486279). The study of acylcarnitines is an active area of research and it is likely that many novel acylcarnitines will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered. An excellent review of the current state of knowledge for acylcarnitines is available at [Dambrova et al. 2021, Physiological Reviews].

   

N-Lauroyl Threonine

2-Dodecanoylamino-3-hydroxybutanoic acid

C16H31NO4 (301.2253)


N-lauroyl threonine belongs to the class of compounds known as N-acylamides. These are molecules characterized by a fatty acyl group linked to a primary amine by an amide bond. More specifically, it is a Lauric acid amide of Threonine. It is believed that there are more than 800 types of N-acylamides in the human body. N-acylamides fall into several categories: amino acid conjugates (e.g., those acyl amides conjugated with amino acids), neurotransmitter conjugates (e.g., those acylamides conjugated with neurotransmitters), ethanolamine conjugates (e.g., those acylamides conjugated to ethanolamine), and taurine conjugates (e.g., those acyamides conjugated to taurine). N-Lauroyl Threonine is an amino acid conjugate. N-acylamides can be classified into 9 different categories depending on the size of their acyl-group: 1) short-chain N-acylamides; 2) medium-chain N-acylamides; 3) long-chain N-acylamides; and 4) very long-chain N-acylamides; 5) hydroxy N-acylamides; 6) branched chain N-acylamides; 7) unsaturated N-acylamides; 8) dicarboxylic N-acylamides and 9) miscellaneous N-acylamides. N-Lauroyl Threonine is therefore classified as a long chain N-acylamide. N-acyl amides have a variety of signaling functions in physiology, including in cardiovascular activity, metabolic homeostasis, memory, cognition, pain, motor control and others (PMID: 15655504). N-acyl amides have also been shown to play a role in cell migration, inflammation and certain pathological conditions such as diabetes, cancer, neurodegenerative disease, and obesity (PMID: 23144998; PMID: 25136293; PMID: 28854168).N-acyl amides can be synthesized both endogenously and by gut microbiota (PMID: 28854168). N-acylamides can be biosynthesized via different routes, depending on the parent amine group. N-acyl ethanolamines (NAEs) are formed via the hydrolysis of an unusual phospholipid precursor, N-acyl-phosphatidylethanolamine (NAPE), by a specific phospholipase D. N-acyl amino acids are synthesized via a circulating peptidase M20 domain containing 1 (PM20D1), which can catalyze the bidirectional the condensation and hydrolysis of a variety of N-acyl amino acids. The degradation of N-acylamides is largely mediated by an enzyme called fatty acid amide hydrolase (FAAH), which catalyzes the hydrolysis of N-acylamides into fatty acids and the biogenic amines. Many N-acylamides are involved in lipid signaling system through interactions with transient receptor potential channels (TRP). TRP channel proteins interact with N-acyl amides such as N-arachidonoyl ethanolamide (Anandamide), N-arachidonoyl dopamine and others in an opportunistic fashion (PMID: 23178153). This signaling system has been shown to play a role in the physiological processes involved in inflammation (PMID: 25136293). Other N-acyl amides, including N-oleoyl-glutamine, have also been characterized as TRP channel antagonists (PMID: 29967167). N-acylamides have also been shown to have G-protein-coupled receptors (GPCRs) binding activity (PMID: 28854168). The study of N-acylamides is an active area of research and it is likely that many novel N-acylamides will be discovered in the coming years. It is also likely that many novel roles in health and disease will be uncovered for these molecules.

   

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

C19H27NO2 (301.2042)


   

1-[(5-Methoxy-3-indolylidene)methylamino]-2-pentylguanidine

5-Methoxyindol-3-carboxaldehyde amino(pentylamino)methylenehydrazone hydrogen maleate

C16H23N5O (301.1903)


   

2,5-Dimethoxy-N-((2-methoxyphenyl)methyl)benzeneethanamine

[2-(2,5-dimethoxyphenyl)ethyl][(2-methoxyphenyl)methyl]amine

C18H23NO3 (301.1678)


   

Dihydroneopine

10-methoxy-4-methyl-12-oxa-4-azapentacyclo[9.6.1.0¹,¹³.0⁵,¹⁷.0⁷,¹⁸]octadeca-7,9,11(18)-trien-14-ol

C18H23NO3 (301.1678)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents D002491 - Central Nervous System Agents > D000700 - Analgesics

   

Deramciclane

dimethyl[2-({1,7,7-trimethyl-2-phenylbicyclo[2.2.1]heptan-2-yl}oxy)ethyl]amine

C20H31NO (301.2406)


   

isoxsuprine

4-{1-hydroxy-2-[(1-phenoxypropan-2-yl)amino]propyl}phenol

C18H23NO3 (301.1678)


   

1-[[(Z)-[5-(Hydroxymethyl)indol-3-ylidene]methyl]amino]-2-pentylguanidine

1-[[(Z)-[5-(Hydroxymethyl)indol-3-ylidene]methyl]amino]-2-pentylguanidine

C16H23N5O (301.1903)


   

6-trans-Piperamide-C-7-1

(6E)-7-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)hept-6-en-1-one

C18H23NO3 (301.1678)


6-trans-piperamide-c-7-1 is a member of the class of compounds known as benzodioxoles. Benzodioxoles are organic compounds containing a benzene ring fused to either isomers of dioxole. Dioxole is a five-membered unsaturated ring of two oxygen atoms and three carbon atoms. 6-trans-piperamide-c-7-1 is practically insoluble (in water) and an extremely weak basic (essentially neutral) compound (based on its pKa). 6-trans-piperamide-c-7-1 can be found in pepper (spice), which makes 6-trans-piperamide-c-7-1 a potential biomarker for the consumption of this food product.

   

ent-kaur-16-en-19-oate

5,9-dimethyl-14-methylidenetetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadecane-5-carboxylate

C20H29O2 (301.2167)


Ent-kaur-16-en-19-oate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Ent-kaur-16-en-19-oate can be found in a number of food items such as tronchuda cabbage, garden rhubarb, quince, and spelt, which makes ent-kaur-16-en-19-oate a potential biomarker for the consumption of these food products.

   

Dihydroerysovine

Dihydroerysovine

C18H23NO3 (301.1678)


   

(-)-Floridinine

(-)-Floridinine

C15H27NO5 (301.1889)


   

Cephalezomine M

Cephalezomine M

C18H23NO3 (301.1678)


   
   

O-Methylmaritidine

O-Methylmaritidine

C18H23NO3 (301.1678)


   
   

(-)-Indolactam V (low PS)

(-)-Indolactam V (low PS)

C17H23N3O2 (301.179)


   
   

1-Hydroxycryprochine

1-Hydroxycryprochine

C18H23NO3 (301.1678)


   

Dihydroerysodine

Dihydroerysodine

C18H23NO3 (301.1678)


   

Phormidinine B

Phormidinine B

C19H27NO2 (301.2042)


   

Thelepogine

Thelepogine

C20H31NO (301.2406)


   

N-Demethylbelladine

N-Demethylbelladine

C18H23NO3 (301.1678)


   
   

Cohirsitinine

Cohirsitinine

C18H23NO3 (301.1678)


   

RACTOPAMINE

RACTOPAMINE

C18H23NO3 (301.1678)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists CONFIDENCE standard compound; INTERNAL_ID 1103

   
   
   
   

N4-[1-Adamantyl(imino)methyl]-3,5-dimethylisoxazole-4-carboxamide

N4-[1-Adamantyl(imino)methyl]-3,5-dimethylisoxazole-4-carboxamide

C17H23N3O2 (301.179)


   
   
   

N-Acetylprimaquine

N-Acetylprimaquine

C17H23N3O2 (301.179)


   

Pyrilamine N-oxide

Pyrilamine N-oxide

C17H23N3O2 (301.179)


CONFIDENCE Tentative identification: most likely structure (Level 3); INTERNAL_ID 1701

   

Trachelanthine

Trachelanthine

C15H27NO5 (301.1889)


Annotation level-1

   

hexadeca-2E, 7Z-dienoic acid pyrrolide

hexadeca-2E, 7Z-dienoic acid pyrrolide

C20H31NO (301.2406)


   

7-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,4-dienamide

7-(1,3-benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,4-dienamide

C18H23NO3 (301.1678)


   
   

(2R)-3-(2,3-Dihydroxy-3-methylbutyl)-5-(3-methylcrotonoyl)indole|(R)-3-(2,3-dihydroxy-3-methylbutyl)-5-(3-methyl-1-oxo-2-butenyl)indole

(2R)-3-(2,3-Dihydroxy-3-methylbutyl)-5-(3-methylcrotonoyl)indole|(R)-3-(2,3-dihydroxy-3-methylbutyl)-5-(3-methyl-1-oxo-2-butenyl)indole

C18H23NO3 (301.1678)


   

(E,E)-2,4-decadienoic acid p-methoxyphenethylamide

(E,E)-2,4-decadienoic acid p-methoxyphenethylamide

C19H27NO2 (301.2042)


   
   

(E,E)-6-(4-Methoxyphenyl)-N-(3-methylbutyl)-2-oxo-3,5-hexadienamide

(E,E)-6-(4-Methoxyphenyl)-N-(3-methylbutyl)-2-oxo-3,5-hexadienamide

C18H23NO3 (301.1678)


   

1-[(2E)-7-(3,4-methylenedioxyphenyl)-2-heptenoyl]pyrrolidine|Piperamide-C7:1(6E)

1-[(2E)-7-(3,4-methylenedioxyphenyl)-2-heptenoyl]pyrrolidine|Piperamide-C7:1(6E)

C18H23NO3 (301.1678)


   

hexadeca-2E,7Z-dien-10-ynoic acid pyrrolidide

hexadeca-2E,7Z-dien-10-ynoic acid pyrrolidide

C20H31NO (301.2406)


   

3beta,6-dimethoxy-10-methyl-galantham-1-ene|galanthamine|Galanthaminmethylaether|O-methyl-chlidanthine|O-methyl-galanthamine

3beta,6-dimethoxy-10-methyl-galantham-1-ene|galanthamine|Galanthaminmethylaether|O-methyl-chlidanthine|O-methyl-galanthamine

C18H23NO3 (301.1678)


   

N-Methyllauformine

N-Methyllauformine

C18H23NO3 (301.1678)


   

(-)-[4aS-(4aalpha,6beta,8aR)]-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepine-6-ol|galanthamine

(-)-[4aS-(4aalpha,6beta,8aR)]-4a,5,9,10,11,12-hexahydro-3-methoxy-11-methyl-6H-benzofuro[3a,3,2-ef][2]benzazepine-6-ol|galanthamine

C18H23NO3 (301.1678)


   

Haminol 4|Haminol-4

Haminol 4|Haminol-4

C19H27NO2 (301.2042)


   

CHEMBL2229478

CHEMBL2229478

C19H27NO2 (301.2042)


   

CHEMBL1762796

CHEMBL1762796

C18H23NO3 (301.1678)


   
   

(+-)-8,9,11,12-Tetrahydroglaziovin|(+-)-Tetrahydroglaziovin|N-Methyl-dihydro-crotsparinin|N-Methyltetrahydrocrotsparine|Tetrahydro-glaziovin

(+-)-8,9,11,12-Tetrahydroglaziovin|(+-)-Tetrahydroglaziovin|N-Methyl-dihydro-crotsparinin|N-Methyltetrahydrocrotsparine|Tetrahydro-glaziovin

C18H23NO3 (301.1678)


   

9-Hydroxy-1-Methyl-2-nonyl-4(1H)-quinolinone

9-Hydroxy-1-Methyl-2-nonyl-4(1H)-quinolinone

C19H27NO2 (301.2042)


   

hexadeca-6E,8E-dien-10-ynoic acid pyrrolidide

hexadeca-6E,8E-dien-10-ynoic acid pyrrolidide

C20H31NO (301.2406)


   

(-)-8,9-dihydrolinearisine

(-)-8,9-dihydrolinearisine

C18H23NO3 (301.1678)


   
   

Dihydroerysodin

Dihydroerysodin

C18H23NO3 (301.1678)


   

2,9-Pentadecadiene-12,14-diynoic acid(2-hydroxyisobutyl)amide|pentadeca-2t,9c-dien-12,14-diynoic acid (2-hydroxyisobutyl)amide

2,9-Pentadecadiene-12,14-diynoic acid(2-hydroxyisobutyl)amide|pentadeca-2t,9c-dien-12,14-diynoic acid (2-hydroxyisobutyl)amide

C19H27NO2 (301.2042)


   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

Dihydrocodeine

Dihydrocodeine

C18H23NO3 (301.1678)


D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants > D009294 - Narcotics D002492 - Central Nervous System Depressants > D009294 - Narcotics > D053610 - Opiate Alkaloids N - Nervous system > N02 - Analgesics > N02A - Opioids > N02AA - Natural opium alkaloids D018373 - Peripheral Nervous System Agents > D018689 - Sensory System Agents C78272 - Agent Affecting Nervous System > C67413 - Opioid Receptor Agonist D002491 - Central Nervous System Agents > D000700 - Analgesics CONFIDENCE standard compound; INTERNAL_ID 2178 CONFIDENCE standard compound; EAWAG_UCHEM_ID 3333 INTERNAL_ID 2178; CONFIDENCE standard compound

   

dobutamine

dobutamine

C18H23NO3 (301.1678)


C - Cardiovascular system > C01 - Cardiac therapy > C01C - Cardiac stimulants excl. cardiac glycosides > C01CA - Adrenergic and dopaminergic agents D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent D020011 - Protective Agents > D002316 - Cardiotonic Agents D002317 - Cardiovascular Agents

   

HELIOCURASSAVICINE N-OXYDE

NCGC00160190-01!HELIOCURASSAVICINE N-OXYDE

C15H27NO5 (301.1889)


   

PRI_302.1864_17.0

PRI_302.1864_17.0

C17H23N3O2 (301.179)


CONFIDENCE Tentative identification: most likely structure (Level 3); INTERNAL_ID 1604

   

Tegaserod

Tegaserod

C16H23N5O (301.1903)


D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D017366 - Serotonin Receptor Agonists A - Alimentary tract and metabolism > A06 - Drugs for constipation > A06A - Drugs for constipation C78272 - Agent Affecting Nervous System > C66885 - Serotonin Antagonist Tegaserod is an orally active serotonin receptor 4 (HTR4; 5-HT4R) agonist and a 5-HT2B receptor antagonist. Tegaserod has pKis of 7.5, 8.4 and 7.0 for human recombinant 5-HT2A, 5-HT2B and 5-HT2C receptors, respectively. Tegaserod causes tumor cell apoptosis, blunts PI3K/Akt/mTOR signaling and decreases S6 phosphorylation. Tegaserod has anti-tumor activity and has the potential for irritable bowel syndrome (IBS) research[1][2][3].

   

Trachelanthamine oxide

Trachelanthamine oxide

C15H27NO5 (301.1889)


Origin: Plant; Formula(Parent): C15H27NO5; Bottle Name:Trachelanthine; PRIME Parent Name:Trachelanthine; PRIME in-house No.:V0316; SubCategory_DNP: Alkaloids derived from ornithine, Pyrrolizidine alkaloids

   

octyltyrazolone

octyltyrazolone

C18H23NO3 (301.1678)


   
   
   
   

3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-ethyl-9-methyl-7-[(phenylacetyl)oxy]-

3-Oxa-9-azoniatricyclo[3.3.1.02,4]nonane, 9-ethyl-9-methyl-7-[(phenylacetyl)oxy]-

C18H23NO3 (301.1678)


   
   
   
   
   

Pentazocine cis-alcohol

Pentazocine cis-alcohol

C19H27NO2 (301.2042)


   
   
   
   
   
   

Cyclohexanone, 4-[1-hydroxy-1-phenyl-3-(1-pyrrolidinyl)propyl]-

Cyclohexanone, 4-[1-hydroxy-1-phenyl-3-(1-pyrrolidinyl)propyl]-

C19H27NO2 (301.2042)


   
   
   
   
   
   

Dimethyl heptanoyl carnitine

2,6 dimethylheptanoyl carnitine

C16H31NO4 (301.2253)


   

(E,E)-Futoamide

(2E,6E)-7-(2H-1,3-benzodioxol-5-yl)-N-(2-methylpropyl)hepta-2,6-dienamide

C18H23NO3 (301.1678)


   

Piperamide-C7:1 (6E)

(6Z)-7-(2H-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)hept-6-en-1-one

C18H23NO3 (301.1678)


   

CAR 9:0

3-[(2,6-dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2253)


   

CAR 8:1;O

(Z)-3-hydroxy-5-octenoylcarnitine;3-{[(5Z)-3-hydroxyoct-5-enoyl]oxy}-4-(trimethylammonio)butanoate

C15H27NO5 (301.1889)


   

NA 16:1;O3

N-(3-Hydroxytetradecanoyl) glycine

C16H31NO4 (301.2253)


   

tert-butyl 4-(1H-benzimidazol-2-yl)piperidine-1-carboxylate

tert-butyl 4-(1H-benzimidazol-2-yl)piperidine-1-carboxylate

C17H23N3O2 (301.179)


   

methyltris(methylethylketoxime)silane

methyltris(methylethylketoxime)silane

C13H27N3O3Si (301.1822)


   

TERT-BUTYL 2-((TERT-BUTOXYCARBONYL)AMINO)-4-(OXIRAN-2-YL)BUTANOATE

TERT-BUTYL 2-((TERT-BUTOXYCARBONYL)AMINO)-4-(OXIRAN-2-YL)BUTANOATE

C15H27NO5 (301.1889)


   

N-cyclopentyl-3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzamide

N-cyclopentyl-3-(5,5-dimethyl-1,3,2-dioxaborinan-2-yl)benzamide

C17H24BNO3 (301.1849)


   

Leu-Leu-Gly

H-Leu-Leu-Gly-OH

C14H27N3O4 (301.2001)


A tripeptide composed of two L-leucine units and glycine joined in sequence by peptide linkages.

   

1-Boc-4-(4-Cyanobenzyl)piperazine

1-Boc-4-(4-Cyanobenzyl)piperazine

C17H23N3O2 (301.179)


   

tert-Butyl 3-oxo-2,3-dihydrospiro[indene-1,4-piperidine]-1-carboxylate

tert-Butyl 3-oxo-2,3-dihydrospiro[indene-1,4-piperidine]-1-carboxylate

C18H23NO3 (301.1678)


   

(R)-3-(3-CYCLOPENTYL-1-OXOPROPYL)-(1-PHENYLMETHYL)-2-OXAZOLIDINONE

(R)-3-(3-CYCLOPENTYL-1-OXOPROPYL)-(1-PHENYLMETHYL)-2-OXAZOLIDINONE

C18H23NO3 (301.1678)


   

N-Cyclopropyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

N-Cyclopropyl-2-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)acetamide

C17H24BNO3 (301.1849)


   

N-cyclopropyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

N-cyclopropyl-2-[3-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl]acetamide

C17H24BNO3 (301.1849)


   

1,4-Piperidinedicarboxylic acid, 4-(2-hydroxyethyl)-, 1-(1,1-dimethylethyl) 4-ethyl ester

1,4-Piperidinedicarboxylic acid, 4-(2-hydroxyethyl)-, 1-(1,1-dimethylethyl) 4-ethyl ester

C15H27NO5 (301.1889)


   

1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-HYDROXY-4-PIPERIDINEPROPANOIC ACID ETHYL ESTER

1-[(1,1-DIMETHYLETHOXY)CARBONYL]-4-HYDROXY-4-PIPERIDINEPROPANOIC ACID ETHYL ESTER

C15H27NO5 (301.1889)


   

3-Azaspiro[5.5]undecane-3-carboxylic acid, 9-oxo-,phenylmethyl ester

3-Azaspiro[5.5]undecane-3-carboxylic acid, 9-oxo-,phenylmethyl ester

C18H23NO3 (301.1678)


   

Dilavase

isoxsuprine

C18H23NO3 (301.1678)


C - Cardiovascular system > C04 - Peripheral vasodilators > C04A - Peripheral vasodilators > C04AA - 2-amino-1-phenylethanol derivatives D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

2-(carboxymethyl-dodecyl-amino)acetic acid

2-(carboxymethyl-dodecyl-amino)acetic acid

C16H31NO4 (301.2253)


   

(R,R)-2,2-(2,6-PYRIDINEDIYL)BIS(4-ISOPROPYL-2-OXAZOLINE)

(R,R)-2,2-(2,6-PYRIDINEDIYL)BIS(4-ISOPROPYL-2-OXAZOLINE)

C17H23N3O2 (301.179)


   

4-(1-Methyl-4-piperidyl)phenylboronic Acid Pinacol Ester

4-(1-Methyl-4-piperidyl)phenylboronic Acid Pinacol Ester

C18H28BNO2 (301.2213)


   

4-(1-PHENETHYL-3-PHENYL-PROPYL)-PYRIDINE

4-(1-PHENETHYL-3-PHENYL-PROPYL)-PYRIDINE

C22H23N (301.183)


   

(S,S)-2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine

(S,S)-2,6-Bis(4-isopropyl-2-oxazolin-2-yl)pyridine

C17H23N3O2 (301.179)


   

buta-1,3-diene,prop-2-enamide,prop-2-enoic acid,styrene

buta-1,3-diene,prop-2-enamide,prop-2-enoic acid,styrene

C18H23NO3 (301.1678)


   

(1R,4aR,4bR,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,6,10,10a-octahydrophenanthrene-1-carboxylate

[1R-(1alpha,4abeta,4balpha,10aalpha)]-1,2,3,4,4a,4b,5,6,10,10a-decahydro-1,4a-dimethyl-7-(isopropyl)phenanthrene-1-carboxylic acid, copper salt

C20H29O2- (301.2167)


   
   

PYRROLIDIN-1-YL(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

PYRROLIDIN-1-YL(3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

C17H24BNO3 (301.1849)


   

PYRROLIDIN-1-YL(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

PYRROLIDIN-1-YL(4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)PHENYL)METHANONE

C17H24BNO3 (301.1849)


   

N-Methyl Etodolac

N-Methyl Etodolac

C18H23NO3 (301.1678)


   

TERT-BUTYL 3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

TERT-BUTYL 3,4-DIHYDRO-2H-SPIRO[NAPHTHALENE-1,4-PIPERIDINE]-1-CARBOXYLATE

C19H27NO2 (301.2042)


   

tert-butyl 4-(1H-indazol-5-yl)piperidine-1-carboxylate

tert-butyl 4-(1H-indazol-5-yl)piperidine-1-carboxylate

C17H23N3O2 (301.179)


   

tert-Butyl 4-pyrrolo[2,3-b]pyridin-1-ylpiperidin-1-carboxylate

tert-Butyl 4-pyrrolo[2,3-b]pyridin-1-ylpiperidin-1-carboxylate

C17H23N3O2 (301.179)


   

tert-butyl spiro[chromene-2,4-piperidine]-1-carboxylate

tert-butyl spiro[chromene-2,4-piperidine]-1-carboxylate

C18H23NO3 (301.1678)


   

S-Bioallethrin

S-Bioallethrin

C19H25O3- (301.1804)


   

(S)-tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate

(S)-tert-Butyl 3-(1H-benzo[d]imidazol-2-yl)piperidine-1-carboxylate

C17H23N3O2 (301.179)


   

2-Cyanoethyltetraisopropylphosphorodiamidite

2-Cyanoethyltetraisopropylphosphorodiamidite

C15H32N3OP (301.2283)


   

Etodolac methyl ester

Etodolac methyl ester

C18H23NO3 (301.1678)


   

ETHYL 1-CYCLOHEXYL-5-HYDROXY-2-METHYL-1H-INDOLE-3-CARBOXYLATE

ETHYL 1-CYCLOHEXYL-5-HYDROXY-2-METHYL-1H-INDOLE-3-CARBOXYLATE

C18H23NO3 (301.1678)


   

1-(TRANS-4-HEXYLCYCLOHEXYL)-4-ISOTHIO-

1-(TRANS-4-HEXYLCYCLOHEXYL)-4-ISOTHIO-

C19H27NS (301.1864)


   

Deramciclane

Deramciclane

C20H31NO (301.2406)


D002492 - Central Nervous System Depressants > D014149 - Tranquilizing Agents > D014151 - Anti-Anxiety Agents D002491 - Central Nervous System Agents > D011619 - Psychotropic Drugs > D014149 - Tranquilizing Agents D018377 - Neurotransmitter Agents > D018490 - Serotonin Agents > D012702 - Serotonin Antagonists D002491 - Central Nervous System Agents > D002492 - Central Nervous System Depressants C78272 - Agent Affecting Nervous System > C28197 - Antianxiety Agent D002491 - Central Nervous System Agents > D000927 - Anticonvulsants Deramciclane has a high affinity for 5-HT2A and 5-HT2C receptors; it acts as an antagonist at both receptor subtypes and has inverse agonist properties at the 5-HT2C receptors without direct stimulatory agonist.

   

1-DODECYLPYRIDINIUM CHLORIDE HYDRATE

1-DODECYLPYRIDINIUM CHLORIDE HYDRATE

C17H32ClNO (301.2172)


   
   

4-(4-Ethoxy-benzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester

4-(4-Ethoxy-benzyl)-3,5-dimethyl-1H-pyrrole-2-carboxylic acid ethyl ester

C18H23NO3 (301.1678)


   

tert-Butyl 4-(2-cyano-4-methylphenyl)piperazine-1-carboxylate

tert-Butyl 4-(2-cyano-4-methylphenyl)piperazine-1-carboxylate

C17H23N3O2 (301.179)


   

N-ethyl-N-propan-2-ylpropan-2-amine,4-methylbenzenesulfonic acid

N-ethyl-N-propan-2-ylpropan-2-amine,4-methylbenzenesulfonic acid

C15H27NO3S (301.1712)


   

4-(2,4-DI-TERT-PENTYLPHENOXY)BUTANENITRILE

4-(2,4-DI-TERT-PENTYLPHENOXY)BUTANENITRILE

C20H31NO (301.2406)


   

4-(PIPERIDIN-1-YLMETHYL)BENZENEBORONIC ACID, PINACOL ESTER 972-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]-1,2-OXAZINANE

4-(PIPERIDIN-1-YLMETHYL)BENZENEBORONIC ACID, PINACOL ESTER 972-[4-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]-1,2-OXAZINANE

C18H28BNO2 (301.2213)


   

tert-butyl-4-(1H-indol-3-yl)piperazine-1-carboxylate

tert-butyl-4-(1H-indol-3-yl)piperazine-1-carboxylate

C17H23N3O2 (301.179)


   

1-Isopropyl Etodolac

1-Isopropyl Etodolac

C18H23NO3 (301.1678)


   

Tert-Butyl 4-(Cyano(Phenyl)Methyl)Piperazine-1-Carboxylate

Tert-Butyl 4-(Cyano(Phenyl)Methyl)Piperazine-1-Carboxylate

C17H23N3O2 (301.179)


   

(4R,4aR,7S,7aR,12bS)-3,7-dimethyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol

(4R,4aR,7S,7aR,12bS)-3,7-dimethyl-1,2,4,4a,5,6,7a,13-octahydro-4,12-methanobenzofuro[3,2-e]isoquinoline-7,9-diol

C18H23NO3 (301.1678)


   

(R)-BoroLeu-(+)-Pinanediol-HCl

(R)-BoroLeu-(+)-Pinanediol-HCl

C15H29BClNO2 (301.198)


   

1-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone

1-(7-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroisoquinolin-2(1H)-yl)ethanone

C17H24BNO3 (301.1849)


   

Tetraethylammonium P-Toluenesulfonate

Tetraethylammonium P-Toluenesulfonate

C15H27NO3S (301.1712)


   

1-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]PIPERIDINE

1-[3-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL]PIPERIDINE

C18H28BNO2 (301.2213)


   
   

Boc-11-aminoundecanoic acid

Boc-11-aminoundecanoic acid

C16H31NO4 (301.2253)


   

N-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)CYCLOPENTANAMINE

N-(2-(4,4,5,5-TETRAMETHYL-1,3,2-DIOXABOROLAN-2-YL)BENZYL)CYCLOPENTANAMINE

C18H28BNO2 (301.2213)


   

(R,R)-3,4-trans-(N-Boc)-diaminopyrrolidine

(R,R)-3,4-trans-(N-Boc)-diaminopyrrolidine

C14H27N3O4 (301.2001)


   
   

N-(6-methoxyquinolin-8-yl)-N-propan-2-yl-pentane-1,4-diamine

N-(6-methoxyquinolin-8-yl)-N-propan-2-yl-pentane-1,4-diamine

C18H27N3O (301.2154)


   

3-(1H-Benzimidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester

3-(1H-Benzimidazol-2-yl)-1-piperidinecarboxylic acid 1,1-dimethylethyl ester

C17H23N3O2 (301.179)


   

N-(1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropyl)acetamide

N-(1-(4-(4,4,5,5-Tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)cyclopropyl)acetamide

C17H24BNO3 (301.1849)


   

3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one

Cis-3-(2,5-dimethylphenyl)-4-hydroxy-8-methoxy-1-azaspiro(4.5)dec-3-en-2-one

C18H23NO3 (301.1678)


   

3-tributylgermylpropan-1-amine

3-tributylgermylpropan-1-amine

C15H35GeN (301.199)


   

Side chain for imipenem

Side chain for imipenem

C14H27NO4Si (301.1709)


   

Benzenemethanol, 4-hydroxy-alpha-(1-((1-methyl-2-phenoxyethyl)amino)ethyl)-

Benzenemethanol, 4-hydroxy-alpha-(1-((1-methyl-2-phenoxyethyl)amino)ethyl)-

C18H23NO3 (301.1678)


D018373 - Peripheral Nervous System Agents > D001337 - Autonomic Agents > D013566 - Sympathomimetics C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist D018377 - Neurotransmitter Agents > D018663 - Adrenergic Agents > D000322 - Adrenergic Agonists C78274 - Agent Affecting Cardiovascular System > C29707 - Vasodilating Agent D012102 - Reproductive Control Agents > D015149 - Tocolytic Agents D002317 - Cardiovascular Agents > D014665 - Vasodilator Agents

   

Indolactam V

Indolactam V

C17H23N3O2 (301.179)


D000890 - Anti-Infective Agents > D000900 - Anti-Bacterial Agents > D007769 - Lactams D009676 - Noxae > D002273 - Carcinogens

   

1-[[(Z)-[5-(Hydroxymethyl)indol-3-ylidene]methyl]amino]-2-pentylguanidine

1-[[(Z)-[5-(Hydroxymethyl)indol-3-ylidene]methyl]amino]-2-pentylguanidine

C16H23N5O (301.1903)


   
   

Levdobutamine

Levdobutamine

C18H23NO3 (301.1678)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist C78274 - Agent Affecting Cardiovascular System > C78322 - Cardiotonic Agent

   

N-(N-L-Leucylglycyl)-L-leucine

N-(N-L-Leucylglycyl)-L-leucine

C14H27N3O4 (301.2001)


   
   

(R)-Dobutamine

(R)-Dobutamine

C18H23NO3 (301.1678)


   

H-Ala-Val-Leu-OH

H-Ala-Val-Leu-OH

C14H27N3O4 (301.2001)


   

3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-ethylpropanamide

3-[3-(4-tert-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-ethylpropanamide

C17H23N3O2 (301.179)


   

Glycyl-L-leucyl-L-leucine

Glycyl-L-leucyl-L-leucine

C14H27N3O4 (301.2001)


   

4-Ethyl-5-hydroxy-7-methyl-6-(1-piperidinylmethyl)-1-benzopyran-2-one

4-Ethyl-5-hydroxy-7-methyl-6-(1-piperidinylmethyl)-1-benzopyran-2-one

C18H23NO3 (301.1678)


   

N-[(1R,2S)-2,6-dimethyl-2,3-dihydro-1H-inden-1-yl]-6-[(1S)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine

N-[(1R,2S)-2,6-dimethyl-2,3-dihydro-1H-inden-1-yl]-6-[(1S)-1-fluoroethyl]-1,3,5-triazine-2,4-diamine

C16H20FN5 (301.1703)


   

Butyl 2-butoxyquinoline-4-carboxylate

Butyl 2-butoxyquinoline-4-carboxylate

C18H23NO3 (301.1678)


   

2-(Diphenethylmethyl)pyridine

2-(Diphenethylmethyl)pyridine

C22H23N (301.183)


   

N-[4-[(6-methoxyquinolin-8-yl)amino]pentyl]acetamide

N-[4-[(6-methoxyquinolin-8-yl)amino]pentyl]acetamide

C17H23N3O2 (301.179)


   

(4-oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

(4-oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl)methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

C15H27NO5 (301.1889)


   

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

(1R,9R,13R)-1,13-Dimethyl-10-[[(2R)-oxolan-2-yl]methyl]-10-azatricyclo[7.3.1.02,7]trideca-2(7),3,5-trien-4-ol

C19H27NO2 (301.2042)


   

ent-kaur-16-en-19-oate

5,9-Dimethyl-14-methylidenetetracyclo[11.2.1.01,10.04,9]hexadecane-5-carboxylate

C20H29O2- (301.2167)


Ent-kaur-16-en-19-oate is practically insoluble (in water) and a weakly acidic compound (based on its pKa). Ent-kaur-16-en-19-oate can be found in a number of food items such as tronchuda cabbage, garden rhubarb, quince, and spelt, which makes ent-kaur-16-en-19-oate a potential biomarker for the consumption of these food products.

   

ent-Kaur-16-en-19-Oate

ent-Kaur-16-en-19-Oate

C20H29O2- (301.2167)


A monocarboxylic acid anion that is the conjugate base of ent-kaur-16-en-19-oic acid, obtained by deprotonation of the carboxy group.

   

(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoate

(5Z,8Z,11Z,14Z,17Z)-Icosa-5,8,11,14,17-pentaenoate

C20H29O2- (301.2167)


   

9beta-Pimara-7,15-dien-19-oate

9beta-Pimara-7,15-dien-19-oate

C20H29O2- (301.2167)


   

(5Z,7E,9E,14Z,17Z)-icosapentaenoate

(5Z,7E,9E,14Z,17Z)-icosapentaenoate

C20H29O2- (301.2167)


The conjugate base of (5Z,7E,9E,14Z,17Z)-icosapentaenoic acid; major species at pH 7.3.

   

kauralexin B1

kauralexin B1

C20H29O2- (301.2167)


   

(1R,4aR,4bS,7S)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2H-phenanthrene-1-carboxylate

(1R,4aR,4bS,7S)-7-ethenyl-1,4a,7-trimethyl-3,4,4b,5,6,8,10,10a-octahydro-2H-phenanthrene-1-carboxylate

C20H29O2- (301.2167)


   

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-ylidene-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylate

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-ylidene-3,4,4b,5,6,9,10,10a-octahydro-2H-phenanthrene-1-carboxylate

C20H29O2- (301.2167)


   

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,9,10,10a-octahydrophenanthrene-1-carboxylate

(1R,4aR,4bS)-1,4a-dimethyl-7-propan-2-yl-2,3,4,4b,5,9,10,10a-octahydrophenanthrene-1-carboxylate

C20H29O2- (301.2167)


   

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,5,6,9,10,10a-octahydrophenanthrene-1-carboxylate

(1R,4aS,10aR)-1,4a-dimethyl-7-propan-2-yl-2,3,4,5,6,9,10,10a-octahydrophenanthrene-1-carboxylate

C20H29O2- (301.2167)


   

5-Oxooctanoylcarnitine

5-Oxooctanoylcarnitine

C15H27NO5 (301.1889)


   

7-Oxooctanoylcarnitine

7-Oxooctanoylcarnitine

C15H27NO5 (301.1889)


   

6-Oxooctanoylcarnitine

6-Oxooctanoylcarnitine

C15H27NO5 (301.1889)


   

4-Oxooctanoylcarnitine

4-Oxooctanoylcarnitine

C15H27NO5 (301.1889)


   

3-Oxooctanoylcarnitine

3-Oxooctanoylcarnitine

C15H27NO5 (301.1889)


   

6-Methyloctanoylcarnitine

6-Methyloctanoylcarnitine

C16H31NO4 (301.2253)


   

5-Methyloctanoylcarnitine

5-Methyloctanoylcarnitine

C16H31NO4 (301.2253)


   

4-Methyloctanoylcarnitine

4-Methyloctanoylcarnitine

C16H31NO4 (301.2253)


   

3-Methyloctanoylcarnitine

3-Methyloctanoylcarnitine

C16H31NO4 (301.2253)


   

2-Hydroxy-5-octenoylcarnitine

2-Hydroxy-5-octenoylcarnitine

C15H27NO5 (301.1889)


   

4-Hydroxy-6-octenoylcarnitine

4-Hydroxy-6-octenoylcarnitine

C15H27NO5 (301.1889)


   

3-Hydroxy-6-octenoylcarnitine

3-Hydroxy-6-octenoylcarnitine

C15H27NO5 (301.1889)


   

2-Hydroxy-4-octenoylcarnitine

2-Hydroxy-4-octenoylcarnitine

C15H27NO5 (301.1889)


   

(2E,4E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)-hepta-2,4-dienamide

(2E,4E)-N-isobutyl-7-(3,4-methylenedioxyphenyl)-hepta-2,4-dienamide

C18H23NO3 (301.1678)


A natural product found in Piper boehmeriaefolium.

   

1-[(2E)-7-(3,4-methylenedioxyphenyl)-2-heptenoyl]pyrrolidine

1-[(2E)-7-(3,4-methylenedioxyphenyl)-2-heptenoyl]pyrrolidine

C18H23NO3 (301.1678)


A natural product found in Piper boehmeriaefolium.

   
   

10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one

10-hydroxy-3-methyl-8-pentyl-2,4-dihydro-1H-[1]benzopyrano[3,4-c]pyridin-5-one

C18H23NO3 (301.1678)


   

(R)-2,6-dimethylheptanoylcarnitine

(R)-2,6-dimethylheptanoylcarnitine

C16H31NO4 (301.2253)


An optically active form of 2,6-dimethylheptanoylcarnitine having (R)-configuration.

   

[(1R)-4-Oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl]methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

[(1R)-4-Oxido-2,3,5,6,7,8-hexahydro-1H-pyrrolizin-4-ium-1-yl]methyl 2-hydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

C15H27NO5 (301.1889)


   
   
   

4-[(1R)-1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol

4-[(1R)-1-hydroxy-2-(1-phenoxypropan-2-ylamino)propyl]phenol

C18H23NO3 (301.1678)


   

N-[(2,4-Dimethylphenyl)methyl]-2-oxo-1-oxaspiro[4.4]nonane-4-carboxamide

N-[(2,4-Dimethylphenyl)methyl]-2-oxo-1-oxaspiro[4.4]nonane-4-carboxamide

C18H23NO3 (301.1678)


   

N-(4-{(E)-[2-(2-cyclohexylacetyl)hydrazono]methyl}phenyl)acetamide

N-(4-{(E)-[2-(2-cyclohexylacetyl)hydrazono]methyl}phenyl)acetamide

C17H23N3O2 (301.179)


   
   

N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine

N-(2,6-dimethylindan-1-yl)-6-(1-fluoroethyl)-1,3,5-triazine-2,4-diamine

C16H20FN5 (301.1703)


   
   
   
   
   
   
   
   
   
   
   

O-nonanoyl-L-carnitine

O-nonanoyl-L-carnitine

C16H31NO4 (301.2253)


The L-enantiomer of O-nonanoylcarnitine.

   

(1S,7R,8R,14S)-15,17-diazatetracyclo[12.2.2.1(3,7).1(8,12)]icosa-3(20),12(19)-diene-6,9-dione

(1S,7R,8R,14S)-15,17-diazatetracyclo[12.2.2.1(3,7).1(8,12)]icosa-3(20),12(19)-diene-6,9-dione

C18H25N2O2+ (301.1916)


   

3-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-ethylpropanamide

3-[3-(4-butylphenyl)-1,2,4-oxadiazol-5-yl]-N-ethylpropanamide

C17H23N3O2 (301.179)


   

Ent-butopamine

Ent-butopamine

C18H23NO3 (301.1678)


   
   
   
   
   
   
   
   
   

4-[(1R)-1-hydroxy-2-{[(2S)-4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl]phenol

4-[(1R)-1-hydroxy-2-{[(2S)-4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl]phenol

C18H23NO3 (301.1678)


   

4-[(1S)-1-hydroxy-2-{[(2R)-4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl]phenol

4-[(1S)-1-hydroxy-2-{[(2R)-4-(4-hydroxyphenyl)butan-2-yl]amino}ethyl]phenol

C18H23NO3 (301.1678)


   

N-tetradecanoyl-(2S)-hydroxyglycine

N-tetradecanoyl-(2S)-hydroxyglycine

C16H31NO4 (301.2253)


   

All-trans-13,14-dihydroretinoate

All-trans-13,14-dihydroretinoate

C20H29O2- (301.2167)


   

2-[(3S)-1-(cyclohexylmethyl)pyrrolidin-3-yl]-6-luoro-1H-benzimidazole

2-[(3S)-1-(cyclohexylmethyl)pyrrolidin-3-yl]-6-luoro-1H-benzimidazole

C18H24FN3 (301.1954)


   

5-[4-(3-Acetamidopropylamino)butylamino]-5-oxopentanoic acid

5-[4-(3-Acetamidopropylamino)butylamino]-5-oxopentanoic acid

C14H27N3O4 (301.2001)


   

5-[3-(4-Acetamidobutylamino)propylamino]-5-oxopentanoic acid

5-[3-(4-Acetamidobutylamino)propylamino]-5-oxopentanoic acid

C14H27N3O4 (301.2001)


   

N-Piperoyl-N,N-diisopropylamine

N-Piperoyl-N,N-diisopropylamine

C18H23NO3 (301.1678)


   

N-Piperoyl-N,N-dipropylamine

N-Piperoyl-N,N-dipropylamine

C18H23NO3 (301.1678)


   

N-(1,3-dihydroxypentadecan-2-yl)acetamide

N-(1,3-dihydroxypentadecan-2-yl)acetamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxynonan-2-yl)octanamide

N-(1,3-dihydroxynonan-2-yl)octanamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxyoctan-2-yl)nonanamide

N-(1,3-dihydroxyoctan-2-yl)nonanamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxydecan-2-yl)heptanamide

N-(1,3-dihydroxydecan-2-yl)heptanamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxytetradecan-2-yl)propanamide

N-(1,3-dihydroxytetradecan-2-yl)propanamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxytridecan-2-yl)butanamide

N-(1,3-dihydroxytridecan-2-yl)butanamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxyundecan-2-yl)hexanamide

N-(1,3-dihydroxyundecan-2-yl)hexanamide

C17H35NO3 (301.2617)


   

N-(1,3-dihydroxydodecan-2-yl)pentanamide

N-(1,3-dihydroxydodecan-2-yl)pentanamide

C17H35NO3 (301.2617)


   

Benzyl 5-ethoxymethyl-4-ethyl-3-methyl-2-carboxylate

Benzyl 5-ethoxymethyl-4-ethyl-3-methyl-2-carboxylate

C18H23NO3 (301.1678)


   

trihexyphenidyl

Trihexylphenedyl

C20H31NO (301.2406)


D002491 - Central Nervous System Agents > D018726 - Anti-Dyskinesia Agents > D000978 - Antiparkinson Agents N - Nervous system > N04 - Anti-parkinson drugs > N04A - Anticholinergic agents > N04AA - Tertiary amines C78272 - Agent Affecting Nervous System > C66880 - Anticholinergic Agent > C29704 - Antimuscarinic Agent D018377 - Neurotransmitter Agents > D018678 - Cholinergic Agents > D018680 - Cholinergic Antagonists C78272 - Agent Affecting Nervous System > C38149 - Antiparkinsonian Agent

   

(E,E,E)-N-(2-Methylpropyl)hexadeca-2,6,8-trien-10-ynamide

(E,E,E)-N-(2-Methylpropyl)hexadeca-2,6,8-trien-10-ynamide

C20H31NO (301.2406)


   
   

Nonanoylcarnitine

Nonanoylcarnitine

C16H31NO4 (301.2253)


   

3-[(2,6-dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

3-[(2,6-dimethylheptanoyl)oxy]-4-(trimethylazaniumyl)butanoate

C16H31NO4 (301.2253)


   

butopamine

butopamine

C18H23NO3 (301.1678)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

   

2,5-Dimethoxy-N-((2-methoxyphenyl)methyl)benzeneethanamine

2,5-Dimethoxy-N-((2-methoxyphenyl)methyl)benzeneethanamine

C18H23NO3 (301.1678)


   

3-hydroxy-cis-5-octenoylcarnitine

3-hydroxy-cis-5-octenoylcarnitine

C15H27NO5 (301.1889)


An O-acylcarnitine having 3-hydroxy-cis-5-octenoyl as the acyl substituent.

   

7-Methyloctanoylcarnitine

7-Methyloctanoylcarnitine

C16H31NO4 (301.2253)


   

(6E)-Piperamide-C7:1

(6E)-Piperamide-C7:1

C18H23NO3 (301.1678)


   

O-nonanoylcarnitine

O-nonanoylcarnitine

C16H31NO4 (301.2253)


A C9-acylcarnitine having nonanoyl as the acyl substituent.

   

all-cis-5,8,11,14,17-icosapentaenoate

all-cis-5,8,11,14,17-icosapentaenoate

C20H29O2 (301.2167)


An icosapentaenoate that is the conjugate base of all-cis-5,8,11,14,17-icosapentaenoic acid, arising from deprotonation of the carboxylic acid group.

   

2,6-Dimethylheptanoyl carnitine

2,6-Dimethylheptanoyl carnitine

C16H31NO4 (301.2253)


A C9-acylcarnitine in which the acyl group specified is 2,6-dimethylheptanoyl.

   
   
   
   
   
   
   

CAR 7:0;2Me,6Me

CAR 7:0;2Me,6Me

C16H31NO4 (301.2253)


   
   
   
   
   

5,11-dimethoxy-1h,2h,4h,5h,10h,11h,13ah-indolo[7a,1-a]isoquinolin-8-ol

5,11-dimethoxy-1h,2h,4h,5h,10h,11h,13ah-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

(5s,9bs,11r,13as)-5,11-dimethoxy-1h,2h,4h,5h,10h,11h,13ah-indolo[7a,1-a]isoquinolin-8-ol

(5s,9bs,11r,13as)-5,11-dimethoxy-1h,2h,4h,5h,10h,11h,13ah-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

(2e,4e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

(2e,4e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

C18H23NO3 (301.1678)


   

(11s)-7,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

(11s)-7,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

10'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraene-4,11'-diol

10'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraene-4,11'-diol

C18H23NO3 (301.1678)


   

(6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

(6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.2042)


   

(2z,4z)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

(2z,4z)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

C18H23NO3 (301.1678)


   

(1s,17s)-17-methoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2,4,6,14-tetraene-4,5-diol

(1s,17s)-17-methoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2,4,6,14-tetraene-4,5-diol

C18H23NO3 (301.1678)


   

1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H31NO (301.2406)


   

7,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

7,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

C20H31NO (301.2406)


   

(5r,9bs,11r,13ar)-5,11-dimethoxy-1h,2h,4h,5h,10h,11h,13ah-indolo[7a,1-a]isoquinolin-8-ol

(5r,9bs,11r,13ar)-5,11-dimethoxy-1h,2h,4h,5h,10h,11h,13ah-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

[(3,4-dimethoxyphenyl)methyl][2-(4-methoxyphenyl)ethyl]amine

[(3,4-dimethoxyphenyl)methyl][2-(4-methoxyphenyl)ethyl]amine

C18H23NO3 (301.1678)


   

1-hydroxycryprochine

NA

C18H23NO3 (301.1678)


{"Ingredient_id": "HBIN002650","Ingredient_name": "1-hydroxycryprochine","Alias": "NA","Ingredient_formula": "C18H23NO3","Ingredient_Smile": "CN1CCC2=CC(=C(C3=C2C1CC34CCC(C=C4)O)O)OC","Ingredient_weight": "301.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "9947","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "101140029","DrugBank_id": "NA"}

   

(3z,5z)-n-isobutyl-8-(3',4'-methylenedioxy-phenyl)-heptadienamide

NA

C18H23NO3 (301.1678)


{"Ingredient_id": "HBIN009765","Ingredient_name": "(3z,5z)-n-isobutyl-8-(3',4'-methylenedioxy-phenyl)-heptadienamide","Alias": "NA","Ingredient_formula": "C18H23NO3","Ingredient_Smile": "CC(C)CNC(=O)C=CC=CCCC1=CC2=C(C=C1)OCO2","Ingredient_weight": "301.4 g/mol","OB_score": "NA","CAS_id": "NA","SymMap_id": "NA","TCMID_id": "11277","TCMSP_id": "NA","TCM_ID_id": "NA","PubChem_id": "643765","DrugBank_id": "NA"}

   

(1r,10r,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

(1r,10r,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

C18H23NO3 (301.1678)


   

13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C17H23N3O2 (301.179)


   

(2s,4e,6e)-12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

(2s,4e,6e)-12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

C19H27NO2 (301.2042)


   

(2e,6e,8e)-n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

(2e,6e,8e)-n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

C20H31NO (301.2406)


   

4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraene

4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraene

C18H23NO3 (301.1678)


   

hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

C15H27NO5 (301.1889)


   

(1s,10r,17s)-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraene

(1s,10r,17s)-4,5-dimethoxy-16-methyl-9-oxa-16-azatetracyclo[8.7.0.0²,⁷.0¹³,¹⁷]heptadeca-2(7),3,5,12-tetraene

C18H23NO3 (301.1678)


   

(1r,10s,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

(1r,10s,12s)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

C18H23NO3 (301.1678)


   

(2r,6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

(2r,6e,8e)-12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.2042)


   

12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

12-(pyridin-3-yl)dodeca-4,6-dien-2-yl acetate

C19H27NO2 (301.2042)


   

(2e,9z)-n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

(2e,9z)-n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

C19H27NO2 (301.2042)


   

(2e,6e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,6-dienimidic acid

(2e,6e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,6-dienimidic acid

C18H23NO3 (301.1678)


   

(2e,7z)-1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

(2e,7z)-1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

C20H31NO (301.2406)


   

7-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)hept-6-en-1-one

7-(2h-1,3-benzodioxol-5-yl)-1-(pyrrolidin-1-yl)hept-6-en-1-one

C18H23NO3 (301.1678)


   

1-{3-[(2r)-2,3-dihydroxy-3-methylbutyl]-1h-indol-5-yl}-3-methylbut-2-en-1-one

1-{3-[(2r)-2,3-dihydroxy-3-methylbutyl]-1h-indol-5-yl}-3-methylbut-2-en-1-one

C18H23NO3 (301.1678)


   

1-[3-(2,3-dihydroxy-3-methylbutyl)-1h-indol-5-yl]-3-methylbut-2-en-1-one

1-[3-(2,3-dihydroxy-3-methylbutyl)-1h-indol-5-yl]-3-methylbut-2-en-1-one

C18H23NO3 (301.1678)


   

(9bs,11s)-7,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

(9bs,11s)-7,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

[(4as,6ar,10as,11ar,11br)-4,6a,10,11b-tetramethyl-1h,2h,5h,6h,8h,10ah,11h,11ah-naphtho[1,2-b]pyrrolizin-4a-yl]methanol

[(4as,6ar,10as,11ar,11br)-4,6a,10,11b-tetramethyl-1h,2h,5h,6h,8h,10ah,11h,11ah-naphtho[1,2-b]pyrrolizin-4a-yl]methanol

C20H31NO (301.2406)


   

(2s,4s)-1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl propanoate

(2s,4s)-1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl propanoate

C18H23NO3 (301.1678)


   

(9bs,11s)-8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-7-ol

(9bs,11s)-8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-7-ol

C18H23NO3 (301.1678)


   

(9bs,11s)-6,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

(9bs,11s)-6,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

(2e,7z)-1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

(2e,7z)-1-(pyrrolidin-1-yl)hexadeca-2,7-dien-10-yn-1-one

C20H31NO (301.2406)


   

n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

n-(2-methylpropyl)hexadeca-2,6,8-trien-10-ynimidic acid

C20H31NO (301.2406)


   

2,11-dimethoxy-1h,2h,3h,5h,6h,8h,13h-indolo[1,7a-b]isoquinolin-10-ol

2,11-dimethoxy-1h,2h,3h,5h,6h,8h,13h-indolo[1,7a-b]isoquinolin-10-ol

C18H23NO3 (301.1678)


   

(10s,13s)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

(10s,13s)-13-(hydroxymethyl)-10-isopropyl-9-methyl-3,9,12-triazatricyclo[6.6.1.0⁴,¹⁵]pentadeca-1,4,6,8(15),11-pentaen-11-ol

C17H23N3O2 (301.179)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2s)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H27NO5 (301.1889)


   

(2e,4e)-n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

(2e,4e)-n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

C19H27NO2 (301.2042)


   

9,14-dimethoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraene

9,14-dimethoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraene

C18H23NO3 (301.1678)


   

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbutanamide

n-[2-(2,2-dimethylchromen-6-yl)ethyl]-n,3-dimethylbutanamide

C19H27NO2 (301.2042)


   

(4's)-10'-hydroxy-11'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),8',10'-trien-4-one

(4's)-10'-hydroxy-11'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),8',10'-trien-4-one

C18H23NO3 (301.1678)


   

10'-hydroxy-11'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),8',10'-trien-4-one

10'-hydroxy-11'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(12'),8',10'-trien-4-one

C18H23NO3 (301.1678)


   

(9bs)-6,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

(9bs)-6,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

C18H23NO3 (301.1678)


   

8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-12-ol

8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-12-ol

C18H23NO3 (301.1678)


   

n-{3-hydroxy-5-[(3e,5e)-6-methyl-7-oxonona-3,5-dien-1-yl]phenyl}ethanimidic acid

n-{3-hydroxy-5-[(3e,5e)-6-methyl-7-oxonona-3,5-dien-1-yl]phenyl}ethanimidic acid

C18H23NO3 (301.1678)


   

(1s,12s,14r)-9,14-dimethoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraene

(1s,12s,14r)-9,14-dimethoxy-4-methyl-11-oxa-4-azatetracyclo[8.6.1.0¹,¹².0⁶,¹⁷]heptadeca-6,8,10(17),15-tetraene

C18H23NO3 (301.1678)


   

12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

12-(pyridin-2-yl)dodeca-6,8-dien-2-yl acetate

C19H27NO2 (301.2042)


   

(7-hydroxy-hexahydro-1h-pyrrolizin-1-yl)methyl 2,3-dihydroxy-2-isopropylbutanoate

(7-hydroxy-hexahydro-1h-pyrrolizin-1-yl)methyl 2,3-dihydroxy-2-isopropylbutanoate

C15H27NO5 (301.1889)


   

1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

1-(pyrrol-1-yl)hexadeca-2,7-dien-1-one

C20H31NO (301.2406)


   

1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl propanoate

1-(1h-indol-3-yl)-4-methyl-3-oxohexan-2-yl propanoate

C18H23NO3 (301.1678)


   

8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-7-ol

8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-7-ol

C18H23NO3 (301.1678)


   

4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

C18H23NO3 (301.1678)


   

[(1s,7r,7ar)-7-hydroxy-hexahydro-1h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

[(1s,7r,7ar)-7-hydroxy-hexahydro-1h-pyrrolizin-1-yl]methyl (2s)-2-hydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H27NO5 (301.1889)


   

(6e,8e)-1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

(6e,8e)-1-(pyrrolidin-1-yl)hexadeca-6,8-dien-10-yn-1-one

C20H31NO (301.2406)


   

(1s,4s,4'r)-10'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraene-4,11'-diol

(1s,4s,4'r)-10'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraene-4,11'-diol

C18H23NO3 (301.1678)


   

(1s,10r,12r)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

(1s,10r,12r)-4,5,12-trimethoxy-9-azatetracyclo[7.5.2.0¹,¹⁰.0²,⁷]hexadeca-2(7),3,5,13-tetraene

C18H23NO3 (301.1678)


   

n'-({[(3z)-5-(hydroxymethyl)indol-3-ylidene]methyl}amino)-n-pentylguanidine

n'-({[(3z)-5-(hydroxymethyl)indol-3-ylidene]methyl}amino)-n-pentylguanidine

C16H23N5O (301.1903)


   

(2z,4e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

(2z,4e)-7-(2h-1,3-benzodioxol-5-yl)-n-(2-methylpropyl)hepta-2,4-dienimidic acid

C18H23NO3 (301.1678)


   

(1r,7as)-1-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

(1r,7as)-1-({[(2s)-2-hydroxy-2-[(1r)-1-hydroxyethyl]-3-methylbutanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

C15H27NO5 (301.1889)


   

n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

n-[2-(4-methoxyphenyl)ethyl]deca-2,4-dienimidic acid

C19H27NO2 (301.2042)


   

(1s,4r,4'r)-10'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraene-4,11'-diol

(1s,4r,4'r)-10'-methoxy-5'-methyl-5'-azaspiro[cyclohexane-1,2'-tricyclo[6.3.1.0⁴,¹²]dodecane]-1'(11'),2,8'(12'),9'-tetraene-4,11'-diol

C18H23NO3 (301.1678)


   

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

(1r,7as)-hexahydro-1h-pyrrolizin-1-ylmethyl (2r)-2,3-dihydroxy-2-[(1s)-1-hydroxyethyl]-3-methylbutanoate

C15H27NO5 (301.1889)


   

n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

n-(2-hydroxy-2-methylpropyl)pentadeca-2,9-dien-12,14-diynimidic acid

C19H27NO2 (301.2042)


   

methyl 8-(3-methoxy-3-methylbutyl)-2-methylquinoline-4-carboxylate

methyl 8-(3-methoxy-3-methylbutyl)-2-methylquinoline-4-carboxylate

C18H23NO3 (301.1678)


   

n-[3-hydroxy-5-(6-methyl-7-oxonona-3,5-dien-1-yl)phenyl]ethanimidic acid

n-[3-hydroxy-5-(6-methyl-7-oxonona-3,5-dien-1-yl)phenyl]ethanimidic acid

C18H23NO3 (301.1678)


   

(1s,7as)-1-({[(2r)-2,3-dihydroxy-2-isopropylbutanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

(1s,7as)-1-({[(2r)-2,3-dihydroxy-2-isopropylbutanoyl]oxy}methyl)-hexahydro-1h-pyrrolizin-4-ium-4-olate

C15H27NO5 (301.1889)


   

(9bs,11r,12r)-8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-12-ol

(9bs,11r,12r)-8,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-12-ol

C18H23NO3 (301.1678)


   

6,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

6,11-dimethoxy-1h,2h,4h,5h,10h,11h,12h-indolo[7a,1-a]isoquinolin-8-ol

C18H23NO3 (301.1678)


   

hexahydro-1h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

hexahydro-1h-pyrrolizin-1-ylmethyl 2,3-dihydroxy-2-(1-hydroxyethyl)-3-methylbutanoate

C15H27NO5 (301.1889)


   

17-methoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2,4,6,14-tetraene-4,5-diol

17-methoxy-11-azatetracyclo[9.7.0.0¹,¹⁴.0²,⁷]octadeca-2,4,6,14-tetraene-4,5-diol

C18H23NO3 (301.1678)